Conatus Pharmaceutic
NASDAQ:CNAT (5/26/2020, 7:04:43 PM)
After market: 0.54 -0.02 (-2.88%)0.556
+0 (+0.18%)
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.
Conatus Pharmaceutic
16745 W. Bernardo Dr. Suite 250
San Diego CA 92127
P: 858-376-2600
CEO: Steven J. Mento
Histogen (HSTO) has finalized its merger with Conatus Pharmaceuticals (NASDAQ:CNAT). The combined company with do business under the Histogen name with shares trading under the HSTO ticker starting to
XTNT – XTNT leads the way today as the best performing small cap stock, closing up 160.28%.
SNNA – SNNA leads the way today as the best performing small cap stock, closing up 34.46%.
Here you can normally see the latest stock twits on CNAT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: